Concepedia

Starting a new anti‐seizure medication in drug‐resistant epilepsy: Add‐on or substitute?

Mubeen Janmohamed, Nicholas Lawn, Katrina Spilsbury, Josephine Chan, John Dunne

Epilepsia · 2020 · 14 citations · 23 references

DOI

Abstract

Adding or substituting a new ASM in DRE has the same influence on seizure outcomes. The findings confirm that ASM alterations in DRE can be individualized according to concurrent ASM therapy and patient characteristics.

References

23

Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs

Zhibin Chen, Martin J. Brodie, Danny Liew et al. · JAMA Neurology · 2017 · 1.4K citations

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

Anthony G Marson, Asya M Al-Kharusi, Muna Alwaidh et al. · The Lancet · 2007 · 969 citations · Full text

, , +3

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

Anthony G Marson, Asya M Al-Kharusi, Muna Alwaidh et al. · The Lancet · 2007 · 959 citations · Full text

, , +5

Results of treatment changes in patients with apparently drug‐resistant chronic epilepsy

Anna Lisa Luciano, Simon Shorvon · Annals of Neurology · 2007 · 325 citations

Likelihood of seizure remission in an adult population with refractory epilepsy

Brian C. Callaghan, Kishlay Anand, Dale C. Hesdorffer et al. · Annals of Neurology · 2007 · 314 citations